Most patients with advanced melanoma who received pre-surgical...
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients...

New genetic marker linked to improved survival with...
Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations...
MD Anderson achieves sixth Magnet designation in...
The American Nurses Credentialing Center (ANCC) Magnet Recognition Program is the highest honor of excellence in nursing
MD Anderson...
Researchers identify key B-cell lymphoma traits linked with...
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three...

MD Anderson and HealthEx announce collaboration to develop...
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools...
Mailed self-collection HPV tests boost cervical cancer...
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S....
ASCO: New antibody-drug conjugate shows promising safety...
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and,...
ASCO: Pre-surgical combination therapy boosts survival in...
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in...
ASCO: Triple therapy regimen significantly improves...
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs –...
Most Americans unaware of cancer risks associated with...
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just...